target protein dna complexes Search Results


93
Boster Bio mouse anti tfiih
Mouse Anti Tfiih, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pmc12623888-37-0-3?v=Boster+Bio
Average 93 stars, based on 1 article reviews
mouse anti tfiih - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
Boster Bio p46 monoclonal antibody
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
P46 Monoclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pm27234543-59-47-58?v=Boster+Bio
Average 90 stars, based on 1 article reviews
p46 monoclonal antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
ACADEMIC PRESS INC ec-specific dna–protein complexes
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Ec Specific Dna–Protein Complexes, supplied by ACADEMIC PRESS INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pm08606002-78-27-58?v=ACADEMIC+PRESS+INC
Average 90 stars, based on 1 article reviews
ec-specific dna–protein complexes - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Vaccibody dna plasmid encoding for a protein complex encoding for a targeting factor, an adjuvant and antigens
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Dna Plasmid Encoding For A Protein Complex Encoding For A Targeting Factor, An Adjuvant And Antigens, supplied by Vaccibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pmc05612284-12-21-30?v=Vaccibody
Average 90 stars, based on 1 article reviews
dna plasmid encoding for a protein complex encoding for a targeting factor, an adjuvant and antigens - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare protein-dna complex crystals
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Protein Dna Complex Crystals, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/10__1021_slash_cen___v070n041__p079-49-30-16?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
protein-dna complex crystals - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Antisense Therapeutics therapeutics targeting dna mismatch repair protein gene
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Therapeutics Targeting Dna Mismatch Repair Protein Gene, supplied by Antisense Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/us12234459-421-6-4?v=Antisense+Therapeutics
Average 90 stars, based on 1 article reviews
therapeutics targeting dna mismatch repair protein gene - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
AUTODOCK GmbH dna–protein complexes
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Dna–Protein Complexes, supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pm37474674-112-4-9?v=AUTODOCK+GmbH
Average 90 stars, based on 1 article reviews
dna–protein complexes - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co sirnas targeting tar dna-binding protein 43
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Sirnas Targeting Tar Dna Binding Protein 43, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pm37884951-71-0-27?v=Ribobio+co
Average 90 stars, based on 1 article reviews
sirnas targeting tar dna-binding protein 43 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Synergene Biotechnology Group cationic lipids complexed with plasmid dna encoding wild-type p53 tumour suppressor protein
Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary <t>(p46</t> <t>monoclonal</t> antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.
Cationic Lipids Complexed With Plasmid Dna Encoding Wild Type P53 Tumour Suppressor Protein, supplied by Synergene Biotechnology Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pmc05489929-44-9-26?v=Synergene+Biotechnology+Group
Average 90 stars, based on 1 article reviews
cationic lipids complexed with plasmid dna encoding wild-type p53 tumour suppressor protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
SomaLogic the somascan® platform for proteomics profiling uses 4979 somamer® reagents, single-stranded dna aptamers, to 4776 unique human protein targets
Interferon and Inflammatory Pathways Increased by SARS-CoV-2 in BAL and Peripheral Blood of Infected Macaques (A) Circles plot representation of the GSEA NES of interferon and inflammatory pathways (GSEA: FDR ≤ 5%) increased or decreased by SARS-CoV-2 in BAL (left panel) and in peripheral blood (right panel) on days 1, 2, 4, 7, 10, and 14 compared to control animals. An NES greater than 0 (in red) corresponds to a pathway for which member genes are increased by SARS-CoV-2, and an NES below 0 (in blue) corresponds to a pathway for which member genes are decreased by SARS-CoV-2. The size and color of each circle is proportional to the NES, where color gradient ranging from blue (significantly decreased), gray (not significant: FDR ≥ 5%), or red (significantly increased). (B and C) Heatmaps of the log2 transformed fold change of interferon and inflammatory markers in BAL (B) and in peripheral blood (C) that are increased or decreased by SARS-CoV-2 on days 1, 2, 4, 7, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using Benjamini-Hochberg (BH) method. (D) Heatmaps of log2 transformed fold change expression in serum <t>(proteomics)</t> of interferon genes, increased (in red gradient), decreased (in blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using BH method. (E and F) IHC shows increase of MX1 and pSTAT3 on day 2 or day 4 following SARS-CoV-2 challenge. Serial sections of lung tissue showed increased expression of MX1 (type 1 interferon response gene) (E) and phosphorylated STAT3 (Phospho-STAT3 (F). Scale bars, 100 μm. See also <xref ref-type=Figure S4 . " width="250" height="auto" />
The Somascan® Platform For Proteomics Profiling Uses 4979 Somamer® Reagents, Single Stranded Dna Aptamers, To 4776 Unique Human Protein Targets, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pmc07546181-352-4-20?v=SomaLogic
Average 90 stars, based on 1 article reviews
the somascan® platform for proteomics profiling uses 4979 somamer® reagents, single-stranded dna aptamers, to 4776 unique human protein targets - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma plasmid dna encoding green fluorescent protein (gfp) and short hairpin rna targeting oc-2
Interferon and Inflammatory Pathways Increased by SARS-CoV-2 in BAL and Peripheral Blood of Infected Macaques (A) Circles plot representation of the GSEA NES of interferon and inflammatory pathways (GSEA: FDR ≤ 5%) increased or decreased by SARS-CoV-2 in BAL (left panel) and in peripheral blood (right panel) on days 1, 2, 4, 7, 10, and 14 compared to control animals. An NES greater than 0 (in red) corresponds to a pathway for which member genes are increased by SARS-CoV-2, and an NES below 0 (in blue) corresponds to a pathway for which member genes are decreased by SARS-CoV-2. The size and color of each circle is proportional to the NES, where color gradient ranging from blue (significantly decreased), gray (not significant: FDR ≥ 5%), or red (significantly increased). (B and C) Heatmaps of the log2 transformed fold change of interferon and inflammatory markers in BAL (B) and in peripheral blood (C) that are increased or decreased by SARS-CoV-2 on days 1, 2, 4, 7, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using Benjamini-Hochberg (BH) method. (D) Heatmaps of log2 transformed fold change expression in serum <t>(proteomics)</t> of interferon genes, increased (in red gradient), decreased (in blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using BH method. (E and F) IHC shows increase of MX1 and pSTAT3 on day 2 or day 4 following SARS-CoV-2 challenge. Serial sections of lung tissue showed increased expression of MX1 (type 1 interferon response gene) (E) and phosphorylated STAT3 (Phospho-STAT3 (F). Scale bars, 100 μm. See also <xref ref-type=Figure S4 . " width="250" height="auto" />
Plasmid Dna Encoding Green Fluorescent Protein (Gfp) And Short Hairpin Rna Targeting Oc 2, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pm36297592-38-0-16?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
plasmid dna encoding green fluorescent protein (gfp) and short hairpin rna targeting oc-2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
KRUSS GmbH dna-suspended swcnts conjugated with a green fluorescent protein (gfp) targeting nanobody
Interferon and Inflammatory Pathways Increased by SARS-CoV-2 in BAL and Peripheral Blood of Infected Macaques (A) Circles plot representation of the GSEA NES of interferon and inflammatory pathways (GSEA: FDR ≤ 5%) increased or decreased by SARS-CoV-2 in BAL (left panel) and in peripheral blood (right panel) on days 1, 2, 4, 7, 10, and 14 compared to control animals. An NES greater than 0 (in red) corresponds to a pathway for which member genes are increased by SARS-CoV-2, and an NES below 0 (in blue) corresponds to a pathway for which member genes are decreased by SARS-CoV-2. The size and color of each circle is proportional to the NES, where color gradient ranging from blue (significantly decreased), gray (not significant: FDR ≥ 5%), or red (significantly increased). (B and C) Heatmaps of the log2 transformed fold change of interferon and inflammatory markers in BAL (B) and in peripheral blood (C) that are increased or decreased by SARS-CoV-2 on days 1, 2, 4, 7, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using Benjamini-Hochberg (BH) method. (D) Heatmaps of log2 transformed fold change expression in serum <t>(proteomics)</t> of interferon genes, increased (in red gradient), decreased (in blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using BH method. (E and F) IHC shows increase of MX1 and pSTAT3 on day 2 or day 4 following SARS-CoV-2 challenge. Serial sections of lung tissue showed increased expression of MX1 (type 1 interferon response gene) (E) and phosphorylated STAT3 (Phospho-STAT3 (F). Scale bars, 100 μm. See also <xref ref-type=Figure S4 . " width="250" height="auto" />
Dna Suspended Swcnts Conjugated With A Green Fluorescent Protein (Gfp) Targeting Nanobody, supplied by KRUSS GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/target+protein+dna+complexes/pmc11492180-159-19-1?v=KRUSS+GmbH
Average 90 stars, based on 1 article reviews
dna-suspended swcnts conjugated with a green fluorescent protein (gfp) targeting nanobody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary (p46 monoclonal antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.

Journal: Research in veterinary science

Article Title: In vitro protective efficacy of Lithium chloride against Mycoplasma hyopneumoniae infection.

doi: 10.1016/j.rvsc.2016.03.013

Figure Lengend Snippet: Fig. 1. Antibacterial activity of LiCl against M. hyopneumoniae (1 × 106 CCU/ml) infected PK-cells (1 × 105 cells/well). Cells infected with M. hyopneumoniae, XLW-1 for 10 h and treated with LiCl for 12 h. (A) DNA extracted and quantified by qRT–PCR (log10 copies of DNA/well). Data presented as Means ± SD (n = 3). ⁎p b 0.008 and ⁎⁎p b 0.001 vs. control. (B) M. hyopneumoniae treated with LiCl (direct inactivation) before inoculating into cells. (C) Cells treated with LiCl then infected with M. hyopneumoniae, XLW-1 (pre-infection). DNA was extracted and quantified by qRT–PCR as above. A direct effect on bacteria was observed but not in cells. Data presented as Means ± SD (n = 3) ⁎p b 0.05 and p b 0.54 vs. control. (D) Effect of LiCl treatment was evaluated by IFA. Cells washed, fixed and probed with primary (p46 monoclonal antibody) and secondary-FITC conjugated antibodies. FITC- fluorescence was measured at OD 535. ⁎⁎P b 0.001 vs. control.

Article Snippet: We further infected cells (1 × 105 cells/well) in 96-well plates with M. hyopneumoniae (1 × 106 CFU/ml) at 37 °C for 10 h. Cells washed and inoculated LiCl (10–40 mM) for 12 h. Expression level of M. hyopneumoniae surface antigen (p46) was evaluated by IFA using p46 monoclonal antibody (our laboratory) and FITC-conjugated goat antimouse secondary antibodies (Boster Biological Technology Company, China).

Techniques: Activity Assay, Infection, Quantitative RT-PCR, Control, Bacteria

Interferon and Inflammatory Pathways Increased by SARS-CoV-2 in BAL and Peripheral Blood of Infected Macaques (A) Circles plot representation of the GSEA NES of interferon and inflammatory pathways (GSEA: FDR ≤ 5%) increased or decreased by SARS-CoV-2 in BAL (left panel) and in peripheral blood (right panel) on days 1, 2, 4, 7, 10, and 14 compared to control animals. An NES greater than 0 (in red) corresponds to a pathway for which member genes are increased by SARS-CoV-2, and an NES below 0 (in blue) corresponds to a pathway for which member genes are decreased by SARS-CoV-2. The size and color of each circle is proportional to the NES, where color gradient ranging from blue (significantly decreased), gray (not significant: FDR ≥ 5%), or red (significantly increased). (B and C) Heatmaps of the log2 transformed fold change of interferon and inflammatory markers in BAL (B) and in peripheral blood (C) that are increased or decreased by SARS-CoV-2 on days 1, 2, 4, 7, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using Benjamini-Hochberg (BH) method. (D) Heatmaps of log2 transformed fold change expression in serum (proteomics) of interferon genes, increased (in red gradient), decreased (in blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using BH method. (E and F) IHC shows increase of MX1 and pSTAT3 on day 2 or day 4 following SARS-CoV-2 challenge. Serial sections of lung tissue showed increased expression of MX1 (type 1 interferon response gene) (E) and phosphorylated STAT3 (Phospho-STAT3 (F). Scale bars, 100 μm. See also <xref ref-type=Figure S4 . " width="100%" height="100%">

Journal: Cell

Article Title: Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques

doi: 10.1016/j.cell.2020.10.005

Figure Lengend Snippet: Interferon and Inflammatory Pathways Increased by SARS-CoV-2 in BAL and Peripheral Blood of Infected Macaques (A) Circles plot representation of the GSEA NES of interferon and inflammatory pathways (GSEA: FDR ≤ 5%) increased or decreased by SARS-CoV-2 in BAL (left panel) and in peripheral blood (right panel) on days 1, 2, 4, 7, 10, and 14 compared to control animals. An NES greater than 0 (in red) corresponds to a pathway for which member genes are increased by SARS-CoV-2, and an NES below 0 (in blue) corresponds to a pathway for which member genes are decreased by SARS-CoV-2. The size and color of each circle is proportional to the NES, where color gradient ranging from blue (significantly decreased), gray (not significant: FDR ≥ 5%), or red (significantly increased). (B and C) Heatmaps of the log2 transformed fold change of interferon and inflammatory markers in BAL (B) and in peripheral blood (C) that are increased or decreased by SARS-CoV-2 on days 1, 2, 4, 7, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using Benjamini-Hochberg (BH) method. (D) Heatmaps of log2 transformed fold change expression in serum (proteomics) of interferon genes, increased (in red gradient), decreased (in blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 compared to baseline. Differential expression significance was assessed with a corrected p < 0.05 using BH method. (E and F) IHC shows increase of MX1 and pSTAT3 on day 2 or day 4 following SARS-CoV-2 challenge. Serial sections of lung tissue showed increased expression of MX1 (type 1 interferon response gene) (E) and phosphorylated STAT3 (Phospho-STAT3 (F). Scale bars, 100 μm. See also Figure S4 .

Article Snippet: The SomaScan® Platform for proteomics profiling uses 4979 SOMAmer® reagents, single-stranded DNA aptamers, to 4776 unique Human Protein Targets ( https://www.somalogic.com/wp-content/uploads/2016/08/SSM-002-Rev-3-SOMAscan-Technical-White-Paper.pdf ).

Techniques: Infection, Transformation Assay, Expressing

Cytokines and Chemokines Up- or Downregulated by SARS-CoV-2 in BAL, Peripheral Blood, and Serum of Infected Macaques (A and B) (Left panels) Heatmaps of log2 transformed fold change expression of individual cytokines increased (in red gradient), decreased (in blue gradient), or white (not significant) in BAL (A) and peripheral blood (B) on days 1, 2, 4, 7, 10, and 14 compared to baseline. (Right panels) Heatmaps of the GSEA NES of cytokines’ signaling pathways increased (in red gradient), decreased (in blue gradient), or white (not significant) in BAL (A) and peripheral blood (B) on days 1, 2, 4, 7, 10, and 14 compared to baseline. All individual cytokines were significant with a p < 0.05 for at least one time point post-challenge compared to baseline and all cytokines’ signaling pathways were significant with a GSEA nominal p < 0.05 for at least one time point post-challenge compared to baseline. Star symbol indicates individual cytokines or chemokines and pathways that remain significant after correction for multiple comparisons (BH method) or using a FDR of <5%. (C and D) Enrichment plot showing differentially expressed genes (DEGs) that contribute to the positive enrichment of the IL6-JAK-STAT3 signaling pathway on day 2 in BAL (C) and peripheral blood (D) of infected macaques. Plot of the running sum for pathway score in the dataset, including the location of the maximum ES and the leading-edge subset. The red plot shows the ES for the gene set as the analysis walks down the ranked list. The score at the peak of the plot (the score furthest from 0.0) is the ES for the gene set. The small black bars on the x axis show where the members of the gene set appear in the ranked list of genes. The leading-edge subset of a gene set is the subset of members that contribute most to the ES. The leading genes were shown for each plot. (E and F) IHC shows increased expression of IL-6 (E) and IL-10 (F) on day 2 or day 4 following SARS-CoV-2 challenge. Scale bars, 100 μm. (G) Heatmaps of log2 transformed fold change expression in serum (proteomics) of cytokines and chemokines increased (red gradient), decreased (blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 following challenge. Differential expression significance was assessed using a BH-corrected p < 0.05. (H) Cytokine levels measured by the Luminex assay in BAL (top panel) and in serum (lower panel) increased by SARS-CoV-2 in rhesus macaques on days 1, 2, 4, 7, 10, 14, or 35. All the cytokines and chemokines that are significant (Wilcoxon-Mann-Whitney test, p < 0.05) for at least one time point were shown on the heatmaps. Color gradient ranging from white (not significant) to red (highly significant) corresponds to the log2 transformation of the fold change of cytokines’ median levels compared to baseline. See also and .

Journal: Cell

Article Title: Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques

doi: 10.1016/j.cell.2020.10.005

Figure Lengend Snippet: Cytokines and Chemokines Up- or Downregulated by SARS-CoV-2 in BAL, Peripheral Blood, and Serum of Infected Macaques (A and B) (Left panels) Heatmaps of log2 transformed fold change expression of individual cytokines increased (in red gradient), decreased (in blue gradient), or white (not significant) in BAL (A) and peripheral blood (B) on days 1, 2, 4, 7, 10, and 14 compared to baseline. (Right panels) Heatmaps of the GSEA NES of cytokines’ signaling pathways increased (in red gradient), decreased (in blue gradient), or white (not significant) in BAL (A) and peripheral blood (B) on days 1, 2, 4, 7, 10, and 14 compared to baseline. All individual cytokines were significant with a p < 0.05 for at least one time point post-challenge compared to baseline and all cytokines’ signaling pathways were significant with a GSEA nominal p < 0.05 for at least one time point post-challenge compared to baseline. Star symbol indicates individual cytokines or chemokines and pathways that remain significant after correction for multiple comparisons (BH method) or using a FDR of <5%. (C and D) Enrichment plot showing differentially expressed genes (DEGs) that contribute to the positive enrichment of the IL6-JAK-STAT3 signaling pathway on day 2 in BAL (C) and peripheral blood (D) of infected macaques. Plot of the running sum for pathway score in the dataset, including the location of the maximum ES and the leading-edge subset. The red plot shows the ES for the gene set as the analysis walks down the ranked list. The score at the peak of the plot (the score furthest from 0.0) is the ES for the gene set. The small black bars on the x axis show where the members of the gene set appear in the ranked list of genes. The leading-edge subset of a gene set is the subset of members that contribute most to the ES. The leading genes were shown for each plot. (E and F) IHC shows increased expression of IL-6 (E) and IL-10 (F) on day 2 or day 4 following SARS-CoV-2 challenge. Scale bars, 100 μm. (G) Heatmaps of log2 transformed fold change expression in serum (proteomics) of cytokines and chemokines increased (red gradient), decreased (blue gradient), and white (not significant), on days 1, 2, 4, 10, and 14 following challenge. Differential expression significance was assessed using a BH-corrected p < 0.05. (H) Cytokine levels measured by the Luminex assay in BAL (top panel) and in serum (lower panel) increased by SARS-CoV-2 in rhesus macaques on days 1, 2, 4, 7, 10, 14, or 35. All the cytokines and chemokines that are significant (Wilcoxon-Mann-Whitney test, p < 0.05) for at least one time point were shown on the heatmaps. Color gradient ranging from white (not significant) to red (highly significant) corresponds to the log2 transformation of the fold change of cytokines’ median levels compared to baseline. See also and .

Article Snippet: The SomaScan® Platform for proteomics profiling uses 4979 SOMAmer® reagents, single-stranded DNA aptamers, to 4776 unique Human Protein Targets ( https://www.somalogic.com/wp-content/uploads/2016/08/SSM-002-Rev-3-SOMAscan-Technical-White-Paper.pdf ).

Techniques: Infection, Transformation Assay, Expressing, Luminex, MANN-WHITNEY